Showing results (271-280 of 777) with videos related to

Sort By:
Pageof 78
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 19, 2012
Dual inhibition of canonical and noncanonical NF-κB pathways demonstrates significant antitumor activities in multiple myelomaClaire Fabre, Naoya Mimura, Kathryn Bobb, et al.
European Journal of Haematology|February 4, 2012
The potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomibPaul G Richardson, Jacob P Laubach, Robert L Schlossman, et al.
Core Evidence|August 10, 2010
Lenalidomide in multiple myeloma: an evidence-based review of its role in therapyPaul Richardson, Constantine Mitsiades, Jacob Laubach, et al.
Molecular Cancer Therapeutics|April 8, 2010
Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myelomaDiana Cirstea, Teru Hideshima, Scott Rodig, et al.
British Journal of Haematology|June 29, 2006
In vivo and in vitro cytotoxicity of R-etodolac with dexamethasone in glucocorticoid-resistant multiple myeloma cellsPaola Neri, Hiroshi Yasui, Teru Hideshima, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 4, 2015
A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma CellsAnnamaria Gullà, Maria Teresa Di Martino, Maria Eugenia Gallo Cantafio, et al.
British Journal of Haematology|June 24, 2017
MUC1-C is a target in lenalidomide resistant multiple myelomaLi Yin, Ashujit Tagde, Reddy Gali, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2009
High-dose zoledronic acid impacts bone remodeling with effects on osteoblastic lineage and bone mechanical propertiesSamantha Pozzi, Sonia Vallet, Siddhartha Mukherjee, et al.
Cancer Research|June 18, 2014
Selective and potent Akt inhibition triggers anti-myeloma activities and enhances fatal endoplasmic reticulum stress induced by proteasome inhibitionNaoya Mimura, Teru Hideshima, Toshiyasu Shimomura, et al.
Cell Chemical Biology|October 24, 2017
Structure-Guided Development of a Potent and Selective Non-covalent Active-Site Inhibitor of USP7Ilaria Lamberto, Xiaoxi Liu, Hyuk-Soo Seo, et al.
Pageof 78